Show simple item record

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

dc.contributor.authorGullo, Giuseppe
dc.contributor.authorGao, Bo
dc.contributor.authorLi, Siyu
dc.contributor.authorLee, Sue
dc.contributor.authorMcGuire, Kristina
dc.contributor.authorChen, Chieh-
dc.contributor.authorMakharadze, Tamta
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorNechaeva, Marina
dc.contributor.authorSeebach, Frank
dc.contributor.authorWeinreich, David M.
dc.contributor.authorYancopoulos, George D.
dc.contributor.authorLowy, Israel
dc.contributor.authorRietschel, Petra
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKILIÇKAP, SAADETTİN
dc.contributor.authorGÜMÜŞ, MAHMUT
dc.contributor.authorBondarenko, Igor
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorTÜRK, HACI MEHMET
dc.contributor.authorÇİÇİN, İRFAN
dc.contributor.authorBentsion, Dmitry
dc.contributor.authorGladkov, Oleg
dc.contributor.authorClingan, Philip
dc.contributor.authorSriuranpong, Virote
dc.contributor.authorRizvi, Naiyer
dc.date.accessioned2021-12-10T11:09:26Z
dc.date.available2021-12-10T11:09:26Z
dc.date.issued2021
dc.identifier.citationSezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , ÇİÇİN İ., Bentsion D., Gladkov O., et al., "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial", LANCET, cilt.397, sa.10274, ss.592-604, 2021
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_6ae74563-f114-481e-a051-e418bc5ab7e6
dc.identifier.urihttp://hdl.handle.net/20.500.12627/171314
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(21)00228-2
dc.description.abstractBackground We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.
dc.language.isoeng
dc.subjectFundamentals and Skills
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectFamily Practice
dc.subjectGeneral Health Professions
dc.titleCemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentBaşkent Üniversitesi , ,
dc.identifier.volume397
dc.identifier.issue10274
dc.identifier.startpage592
dc.identifier.endpage604
dc.contributor.firstauthorID2533397


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record